All locations will be closing at 4 p.m due to the weather.

CBD Studies Database - CBD + Neurological Pain

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment
Summary: This study investigates the efficacy of Δ9-tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray, a novel cannabinoid formulation, in this 15-week randomized, double-blind, placebo-controlled parallel group study.
Read the full study here.
 .
A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain
Summary: The long-term efficacy of delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray was investigated in this 38-week open-label extension study. 
Read the full study here.
.
Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy
Summary: This study seeks to determine receptor mechanisms by which CBD inhibits CIPN and whether CBD negatively affects nervous system function or chemotherapy efficacy.
Read the full study here
 .
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain
Summary: This study investigates cannabidiol’s effects on 5-HT neuronal activity, as well as its impact on models of neuropathic pain
Read the full study here
.
Single and combined effects of Δ9-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain
Summary: This study tested the possible synergy between CBD and THC in decreasing mechanical sensitivity in a mouse model of paclitaxel-induced neuropathic pain. It also tested the effects of CBD on oxaliplatin- and vincristine-induced mechanical sensitivity.
Read the full study here.
 .
Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial
Summary: The purpose of this extension was to establish long-term tolerability and effectiveness profiles for THC/CBD oromucosal spray in CNP associated with multiple sclerosis.
Read the full study here.
.
The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities
Summary: This study examined the efficacy of a topically delivered cannabidiol (CBD) oil in the management of neuropathic pain in this four-week, randomized and placebo-controlled trial.
Read the full study here.
.
The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain Summary: This study investigated its therapeutic potential on neuropathic (sciatic nerve chronic constriction) and inflammatory pain (complete Freund's adjuvant intraplantar injection) in rats.  Read the full study here.
.
Cannabinoids for Neuropathic Pain
Summary: This article reviews the history, pharmacologic development, clinical trials results, and the future potential of non-smoked, orally bioavailable, non-psychoactive cannabinoids in the management of neuropathic pain.
Read the full study here.
.
The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review
Summary: To carry out a systematic review to assess the effectiveness of cannabis extracts and cannabinoids in the management of chronic nonmalignant neuropathic pain.
Read the full study here.
.
.